Nicotine Modulates Growth Factors and MicroRNA to Promote Inflammatory and Fibrotic Processes

Afshin Ebrahimpour, Samana Shrestha, Mark D. Bonnen, N. Tony Eissa, Ganesh Raghu, and Yohannes T. Ghebre

Departments of Radiation Oncology (A.E., S.S., M.D.B., Y.T.G.) and Medicine, Section on Pulmonary and Critical Care Medicine (N.T.E., Y.T.G.), Baylor College of Medicine, Houston, Texas; and Division of Pulmonary and Critical Care Medicine, Center for Interstitial Lung Disease, University of Washington, Seattle, Washington (G.R.)

Received August 5, 2018; accepted November 1, 2018

ABSTRACT

Idiopathic pulmonary fibrosis (IPF) is a fatal disease that destroys the structure and function of the lungs. Risk factors include advanced age and genetic predisposition. However, tobacco use is the chief modifiable risk factor. The prevalence of tobacco use in IPF reaches up to 80%. Although tobacco smoke contains over 5000 chemicals, nicotine is a major component. Nicotine is a bioactive molecule that acts upon nicotinic acetylcholine receptors expressed on neuronal and non-neuronal cells including endothelial cells. Accordingly, it has a pleiotropic effect on cell proliferation and angiogenesis. The angiogenic effect is partly mediated by stimulation of growth factors including fibroblast, platelet-derived, and vascular endothelial growth factors. Nintedanib, a Food and Drug Administration–approved drug for IPF, works by inhibiting receptors for these growth factors, suggesting a pathobiologic role of the growth factors in IPF and a potential mechanism by which tobacco use may exacerbate the disease process; additionally, nicotine downregulates anti-inflammatory microRNAs (miRs) in lung cells. Here, we profiled the expression of miRs in lung tissues explanted from a lung injury model and examined the effect of nicotine on one of the identified miRs (miR-24) and its downstream targets. Our data show that miR-24 is downregulated during lung injury and is suppressed by nicotine. We also found that nicotine upregulates the expression of inflammatory cytokines targeted by miR-24. Finally, nicotine stimulated growth factors, fibroblast proliferation, collagen release, and expression of myofibroblast markers. Taken together, nicotine, alone or as a component of tobacco smoke, may accelerate the disease process in IPF through stimulation of growth factors and downregulation of anti-inflammatory miRs.

Introduction

Idiopathic pulmonary fibrosis (IPF) is a rare but fatal form of lung fibrosis. It has histologic features of usual interstitial pneumonia with impaired vital capacity and gas exchange, but without evidence for an alternative diagnosis (Raghu et al., 2015). Some of the classic features of IPF are early alveolar inflammation (Kolb et al., 2001; dos Santos et al., 2012) followed by progressive accumulation of collagen, leading to lung scarring, dyspnea, and death within 3–5 years of diagnosis. IPF has an incidence of 93.7 cases and prevalence of 494.5 cases per 100,000 (Raghu et al., 2014). Medical therapies for IPF are suboptimal. Recently, the Food and Drug Administration has approved two drugs, pirfenidone and nintedanib, a Food and Drug Administration–approved drug for IPF, works by inhibiting receptors for these growth factors, suggesting a pathobiologic role of the growth factors in IPF and a potential mechanism by which tobacco use may exacerbate the disease process; additionally, nicotine downregulates anti-inflammatory microRNAs (miRs) in lung cells. Here, we profiled the expression of miRs in lung tissues explanted from a lung injury model and examined the effect of nicotine on one of the identified miRs (miR-24) and its downstream targets. Our data show that miR-24 is downregulated during lung injury and is suppressed by nicotine. We also found that nicotine upregulates the expression of inflammatory cytokines targeted by miR-24. Finally, nicotine stimulated growth factors, fibroblast proliferation, collagen release, and expression of myofibroblast markers. Taken together, nicotine, alone or as a component of tobacco smoke, may accelerate the disease process in IPF through stimulation of growth factors and downregulation of anti-inflammatory miRs. Therefore, there is a compelling need to develop more efficacious therapies. This possibility might be facilitated through complete characterization of the major risk factors that are already linked to IPF. To date, over 140 agents have been associated with the development and/or progression of pulmonary fibrosis. Many of these agents are often encountered through occupational/environmental exposure and include radiation, metal dusts, and asbestos. In addition, genetic polymorphisms and exposure to cigarette smoke are among the risk factors for IPF. Intriguingly, current or former smokers represent a large proportion of IPF patients, ranging from 41% to 83% (Ryu et al., 2001), and have a worse prognosis, including accelerated loss of lung function. Recent epigenetic studies indicate that cigarette smoke is the most strongly associated environmental risk factor for IPF (Yang and Schwartz, 2015). This strong association of tobacco use with IPF suggests that smoking is a chief risk factor in the development and/or progression of the disease (Samara et al., 2011; Margaritopoulos et al., 2015, 2016). In accordance with this consideration, preclinical studies have demonstrated that cigarette smoke causes airway epithelial cell damage (Kuipers et al., 2011; Nyunoya et al., 2014; Solleti et al., 2015) and global epigenetic changes, including DNA...
methylation and chromatin remodeling, which negatively impact genes involved in physiologic lung repair and regeneration (Hagood, 2014; Bellaye and Kolb, 2015; Yang and Schwartz, 2015). However, the precise mechanism by which tobacco use contributes to IPF pathobiology and the effect of nicotine in the disease process are largely unknown. Tobacco smoke contains over 5000 mixtures of toxic and carcinogenic chemicals including nitrosamines, heavy metals, and nicotine (Talhout et al., 2011). Of these components, nicotine is a major ingredient and is responsible for the craving and addictive action. Several studies have reported that nicotine, at clinically relevant concentrations achievable in the plasma of moderate smokers (i.e., 10–100 nM) (Hill et al., 1983; Matta et al., 2007), is biologically active (Duan et al., 2015; Nouri-Shirazi et al., 2015; Schweitzer et al., 2015).

Previously, we (Cooke and Ghebremariam, 2008) and others (Kummer et al., 2008; Mauoche et al., 2009; Kummer and Krasteva-Christ, 2014) have reported that nonexcitable cells (e.g., endothelial and epithelial cells) possess components of the nicotinic acetylcholine (ACh) machinery including nicotinic acetylcholine receptors (nAChRs), acetyltransferase, acetylcholinesterase, and choline transporters (Fig. 1). This machinery is responsible for the production, storage, secretion, and breakdown of ACh; an endogenous hormone that activates nAChRs to exert autocrine and paracrine effects. The nAChRs are composed of five subunits with 16 different isoforms arranged as αβ heteromeric or α homomeric units (α1–α7, α9, α10, β1–β4, δ, γ, and ε; α8 is avian restricted). Studies have shown that lung fibroblasts and epithelial cells express functional nAChRs that are responsive to endogenous agonists such as ACh and to exogenous stimulation by nicotine (Maus et al., 1998; Carlisle et al., 2004). Notably, tobacco exposure does not appear to alter the composition and/or distribution of nAChRs in lung cells (Carlisle et al., 2004). Of the nAChRs expressed in airway cells, the α7 nAChR is relatively well characterized, including its involvement in ion permeability, proliferation, epithelium differentiation, fetal lung development, and function (Sekhon et al., 1999, 2001; Nastrucci and Russo, 2012). It is also the α7 nAChR that is preferentially activated by nicotine (Cooke and Ghebremariam, 2008). As a result, nicotine exerts its detrimental effect on the vascular system including promoting inflammation, collagen turnover, and angiogenesis (Carty et al., 1996; Cucina et al., 2000; Jensen et al., 2012). The angiogenic effect of nicotine is in part mediated by excessive stimulation of growth factors including fibroblast growth factor (FGF), platelet-derived growth factor (PDGF), and vascular endothelial growth factor (VEGF) (Carty et al., 1996; Cucina et al., 2000; Conklin et al., 2002; Ornitz and Itoh, 2015), as well as their receptors (Grozio et al., 2007). Intriguingly, the Food and Drug Administration–approved antifibrotic drug nintedanib (BIBF 1120) works by inhibiting the receptors for FGF, PDGF, and VEGF, suggesting a pathobiological role of these mitogenic growth factors as well as a potential mechanism by which tobacco use may potentiate the disease process in IPF.

Recently, we discovered that nicotine downregulates anti-inflammatory microRNAs (miRs), including miR-24 in primary human lung epithelial and endothelial cells. Many of the predicted targets of miR-24 are proinflammatory cytokines and FGF; stimuli that are known to play a pathophysiological role in IPF. Being highly conserved noncoding RNA molecules that are involved in post-transcriptional repression of genes (Lee et al., 1993), miRs have recently emerged as key modulators of lung disease. To date, several miRs have been demonstrated to play significant roles in the disease process in IPF (Pandit et al., 2010, 2011; Milosevic et al., 2012; Yang et al., 2012, 2013; Lino Cardenas et al., 2013; Montgomery et al., 2014). For example, microarray analysis of normal and IPF lung tissue samples revealed that about 10% of miRs are differentially expressed in IPF lungs (Milosevic et al., 2012). Many of these miRs are predicted to be directly governed by transforming growth factor (TGF) β and are involved in fibrogenesis and aberrant lung remodeling (Pandit and Milosevic, 2015). Recently, the important role of miRs in IPF disease pathogenesis has compelled the National Institutes of Health to support the development of an “IPF map project”; a web-based resource for genomic and transcriptomic profiling of mRNA and miR transcripts derived from IPF lungs.

Little is known about the genomic and epigenetic effects of tobacco smoke or its components in the context of IPF. There are only a limited number of studies that looked at the differential effect of nicotine on miRs. For example, in a canine model of atrial fibrosis Shan et al. (2009) demonstrated that nicotine downregulated two antifibrotic miRs (miR-133 and miR-590), resulting in stimulation of atrial fibroblast proliferation, TGFβ1 expression, and collagen accumulation.

**Fig. 1.** The nicotinic acetylcholine machinery: ACh or nAChRs, including the homeric α7 nAChR promote growth factors (VEGF, FGF, and PDGF) and influence several physiologic processes including cell proliferation, migration, differentiation, and angiogenesis, as well as pathologic conditions, including inflammation and fibrosis. Permeability of the α7 nAChR to cations (e.g., Ca2+) is shown. In addition, the degradation of ACh into choline, the internalization of choline and its recycling to form ACh molecules is shown. Ca2+, calcium; ChAT, choline acetyltransferase; ChE, choline esterase; CHT1, choline transporter.
The nicotine-induced fibrogenesis and downregulation of miRs in that study was mediated by α7 nAChR and was reversed by pretreatment with a selective α7 nAChR antagonist, α-bungarotoxin (Shan et al., 2009). A recent study in Caenorhabditis elegans (C. elegans) demonstrated that nicotine altered the miR expression profile of 17% of the worm’s total miR, accounting for nearly 3000 coregulated genes (Taki et al., 2014). Given that up to 80% of C. elegans genes, including nAChRs, are conserved in humans (Vella and Slack, 2005), this finding has important implications in tobacco-related disease research, including IPF.

In the present study, we examined the effect of nicotine at clinically relevant concentrations on growth factors known to stimulate tyrosine kinase receptors, as well as on anti-inflammatory/antifibrotic miRs including miR-24 and its predicted downstream targets. In addition, we assessed the effect of nicotine on the proliferation of lung fibroblasts and accumulation of collagen.

Materials and Methods

Isolation of MicroRNAs from Bleomycin-Induced Lung Injury Model. Lung fibrosis was established in a rat model of acute lung injury by a single intratracheal instillation of bleomycin as we described previously (Ghebremariam et al., 2015). In brief, anesthetized male Fischer F344 rats were instilled with normal saline (sham) or bleomycin sulfate (4 mg/kg) intratracheally on study day 0 and were followed for 28 days to assess lung inflammation and fibrosis. In the present study, the right lung lobes harvested from the sham and bleomycin-injured animals that did not receive any active drug were used for the microRNA expression study described subsequently. Total RNA (including miRs) was isolated using TRIzol Reagent (Invitrogen, Carlsbad, CA), and the concentration and purity of the RNA samples were validated using a NanoDrop spectrophotometer. Mature miR in the isolated RNA samples was reverse transcribed into cDNA using the TaqMan MicroRNA Reverse Transcription Kit (Applied Biosystems, Foster City, CA). Finally, the cDNA was amplified using a quantitative real-time polymerase chain reaction technique to screen for the expression of miRs that have been linked to tissue inflammation and fibrosis, including miR-17, miR-20, miR-21, miR-24, miR-29, miR-30a, miR-34a, miR-133a, miR-155, miR-199a, miR-214, miR-224, miR-205, miR-335, miR-362, miR-338, miR-377, and miR-483; these miRs have been previously linked to inflammation and/or fibrosis in at least one tissue type.

Amplification of miR-24 in Nicotine-Treated Lung Epithelial Cells. Normal human lung epithelial cells (Lonza, Allendale, NJ) were grown in 75 cm² tissue culture flasks at 37°C/5% CO₂ in bronchial epithelial cell growth media supplemented with serum, growth factors, and antibiotics (Lonza) until about 70% confluence. Next, the cells were treated with nicotine (Sigma, St. Louis, MO) at concentrations achievable in the plasma of smokers (≈500 nM) in the presence of vehicle [phosphate-buffered saline (PBS)] control for 24 hours. Subsequently, the cells were dissociated using Accutase solution (Sigma) treatment for 3 minutes at 37°C. The cells were pelleted down by centrifugation at 600g for 5 minutes and washed with PBS. Subsequently, total RNA (including miRNA and miR) was isolated and purified using miRNeasy Mini Kit (Qiagen, Germantown, MD) following the purveyor’s guide. Finally, miR-24, identified in the aforementioned study, was amplified by quantitative reverse transcription polymerase chain reaction. The miRNA samples were used to run the TaqMan OpenArray Human Inflammation Panel (Life Technologies, Waltham, MA) in 3072-well microfluidic plates coated with TaqMan primers and probes.

Proliferation of Nicotine-Treated Lung Fibroblasts. Normal human lung fibroblasts (Lonza) were cultured in a 9-well plate in FGM-2 media (Lonza) containing 2% fetal bovine serum at 37°C/5% CO₂. The cells (3 × 10⁴) were incubated overnight prior to synchronization by a pulse of serum starvation and low serum (0.1%) for 24 hours. The next day, the cells were stimulated with media containing 10% serum in the presence of nicotine (1–100 nM final concentration) or vehicle (PBS) for another 24 hours. Subsequently, the cells were incubated with 5-bromo-2-deoxyuridine (BrdU; 1:500 dilution) for 22 hours to assess the effect of nicotine on proliferation. The incorporation of BrdU into the DNA of proliferating cells was detected using anti-BrdU antibody followed by absorbance measurement at 450 nm as per the protocol provided in the BrdU Cell Proliferation Assay Kit (Millipore, Burlington, MA).

Gene Expression of Inflammatory and Fibrotic Cytokines Following Treatment with Nicotine or miR-24 Inhibitor. Two micrograms of RNA isolated from the nicotine or miR-24 inhibitor–treated (assay ID: MII10737; has-miR-24-3p; mirVana miRNA inhibitor; Life Technologies) human lung epithelial cells or fibroblasts was reverse transcribed per cell type as described previously. The resulting cDNA was used for gene expression studies to screen for the expression pattern of classic inflammatory cytokines. In addition, the nicotine-treated samples were used to evaluate the expression of additional human inflammation and fibrosis-related genes using the TaqMan OpenArray Human Inflammation Panel (Life Technologies) as described previously. Confirmatory quantitative reverse transcription polymerase chain reaction was performed using standard TaqMan gene expression assay subunit-specific “best coverage” primer/probe sets (Applied Biosystems).

Effect of Nicotine on Soluble Collagen Release. For this study, we seeded normal human lung fibroblasts at a density of 6 × 10⁴ cells/well in six-well plates and cultured them overnight at 37°C/5% CO₂. The next day, the media were aspirated and the cells were rinsed with PBS prior to overnight synchronization as described previously. On day 3, the cells were stimulated with fully supplemented Dulbecco’s modified Eagle’s media (Life Technologies) containing 10% fetal bovine serum in the absence or presence of recombinant TGFβ1 (at 10 ng/ml; Peprotech (Rocky Hill, NJ)) and nicotine (100 nM), miR-24 inhibitor (30 nM), or vehicle for 24 hours. Subsequently, the acid-soluble collagen content in each well was determined in the conditioned media using Biocolor’s Sircol Collagen Assay Kit (Accurate Chemical and Scientific Corp., Westbury, NY) following the recommended protocol. The amount of collagen in each well was estimated from a standard curve and the collagen content in each sample was normalized to the total cellular protein in the respective well. Data were expressed as microgram collagen per milligram of protein.

Effect of Nicotine on Growth Factors: VEGF, FGF, and PDGF. To measure the concentration of VEGF, FGF, and PDGF, primary human lung endothelial cells were seeded on 75 cm² flasks and cultured until about 80% confluence in EBM2 media (Lonza). Subsequently, the cells were treated with nicotine (1–100 nM) or PBS control for 24 hours. Conditioned media were collected and centrifuged at 600g for 5 minutes for enzyme-linked immunosorbent assay (ELISA). The conditioned media and cells were harvested and total protein was extracted for normalization and measurement of intracellular growth factor concentration. For the ELISA assays, the concentration of VEGF was quantified using the Human VEGF ELISA Kit (Life Technologies), the concentration of FGF was measured using the Human FGF Basic Assay Kit (Invitrogen), and the concentration of PDGF was measured using the Human PDGF-BB ELISA Kit (Thermo Scientific, Waltham, MA). In brief, 100 μl standards, cell lysate, or conditioned media (diluted in standard diluent buffer) were added to microtiter wells and incubated for 2 hours at room temperature. The wells were washed prior to incubation with biotinylated antibody for another hour at room temperature. Subsequently, 100 μl of streptavidin/horseradish peroxidase reagent was added to each well, except for the blanks, and incubated for 30 minutes. Finally, the wells were washed and incubated with 100 μl of substrate for detection. Absorbencies were measured at 450 nm and the concentration of growth factor in the samples was calculated from the standard curve.

Immunofluorescence Staining of Lung Fibroblasts Exposed to Prolonged Nicotine Treatment. To assess whether nicotine increases the expression of myofibroblast markers, primary human
lung fibroblasts (Lonza) were seeded in gelatin-coated coverslips immersed in six-well plates in the absence or presence of nicotine (100 nM) for 5 days. Subsequently, the cells were fixed in PBS-diluted 4% paraformaldehyde (ThermoFisher) for 15 minutes at room temperature and rinsed with PBS prior to permeabilization with 0.2% Triton-X (Sigma) for 10 minutes at room temperature. Background signal was blocked with 2% nonfat milk for 1 hour at room temperature and the cells were stained for α smooth muscle actin (1:400; Abcam, Cambridge, UK) and type I collagen (1:500; Abcam). Finally, the cells were rinsed three times in PBS containing 0.5% Tween 20 (Sigma) and stained with goat anti-rabbit (1:500; ThermoFisher) Alexa Fluor 594 secondary antibody. The nuclei were stained with 4',6-diamidino-2-phenylindole (10 mg/ml; ThermoFisher) for 5 minutes and kept in PBS until mounting. Immunofluorescence images were captured using a camera integrated to a Leica DM IL LED fluorescence microscope (Leica Microsystems, Buffalo Grove, IL).

**Statistical Analysis.** GraphPad Prism software (GraphPad, La Jolla, CA) was used to perform statistical tests in the in vitro cell culture studies. Groups of two were compared using Student’s t test, and multiple groups were compared using one-way analysis of variance followed by correction using the Bonferroni post-test.

**Study Approval.** The animal study from which lung tissue was obtained was reviewed and approved by the Lovelace Respiratory Research Institute Vertebrate Animal Use Research Committee, (Albuquerque, NM) (approval FY14-084) as described in Ghebremariam et al. (2015).

**Results**

**Differential Regulation of miR Expression in Experimental Fibrosis.** Among the screened microRNAs, we have successfully confirmed that most of them are detectable in the sham and bleomycin-injured groups. Of these detected miRs, we found that miR-24, -199a, -214, -335, and -483 were significantly changed in the bleomycin-injured fibrotic lungs compared with the sham (P < 0.05) (Supplemental Fig. 1). Because of its novelty in lung injury, we pursued miR-24 for subsequent studies. In a follow-up study, the expression of miR-24 and the housekeeping gene U6 was amplified using the TaqMan MicroRNA Assay (Applied Biosystems). We confirmed that miR-24 was significantly downregulated in the bleomycin-injured lungs (Fig. 2), suggesting a novel role for this miR in lung remodeling.

**Nicotine Downregulates miR-24 Expression.** Given the association of tobacco smoke and dysregulated lung function, we further tested the hypothesis that the major ingredient, nicotine, enhances inflammatory processes at least in part through inhibition of anti-inflammatory miRs. Given its anti-inflammatory role in a tobacco smoke–related disease (Maegdefessel et al., 2014) and association with lung injury in our model, we examined the effect of nicotine on miR-24 in epithelial cells; a cell type with a repertoire of the cholinergic acetylcholine machinery (Lam et al., 2016) and a prominent role in nicotine/tobacco smoke–related lung diseases (Heijink et al., 2012). Treatment of primary human lung epithelial cells at clinically relevant concentrations of nicotine (Hill et al., 1983) revealed dose-dependent reduction of miR-24 expression (Fig. 3). Notably, the dysregulation of miR-24 during the course of lung injury (Fig. 2) and its more pronounced suppression by nicotine (Fig. 3) suggest that cigarette smoke may accelerate the disease process in IPF at least in part due to excessive inhibition of miR-24 and subsequent loss of regulation on predicted miR-24 targets including proinflammatory cytokines. A recent preclinical study reported that miR-24 is involved in vascular inflammation through derepression of proinflammatory cytokines (Maegdefessel et al., 2014). One of the reported key targets of miR-24 is chitinase 3-like 1; a cartilage glycoprotein that is shown to be upregulated in IPF (Zhou et al., 2014).

**miR-24 Regulates Inflammatory Cytokines.** The gene expression study of representative miR-24 target genes after treatment of lung epithelial cells with a miR-24 inhibitor revealed upregulation of these proinflammatory molecules (Fig. 4), indicating that miR-24 indeed targets these cytokines in lung cells. Uregulation of classic inflammatory molecules such as soluble TNF-α, IL1β, and NFκB have been reported in the bleomycin model of lung injury and IPF patients (Serrano-Mollar et al., 2003; Oikonomou et al., 2006; Wilson et al., 2010). Studies have also shown sustained expression of TGFβ in an animal model that overexpresses IL1β (Kolb et al., 2001).

**Nicotine Coregulates Inflammatory Cytokines that Are Regulated by miR-24.** Pretreatment of lung epithelial cells with nicotine also mirrored derepression of the
signals (Heeschen et al., 2001; Cooke and Ghebremariam, nAChR; CHRNA7); a major subunit through which nicotine
to IL2RB), IL17B, IL21 receptor, interferon
subunit B (IL2RB), IL17B, IL21 receptor, interferon
expression of proinflammatory genes was amplified by reverse transcription
polymerase chain reaction. The housekeeping gene β-actin was used
as the internal control and data were normalized to the control group.
Data are mean ± S.E.M. from duplicate experiments (n = 4). *P < 0.05 vs. control.

Nicotine and miR-24 Regulate Lung Cell Proliferation. Our proliferation study of human lung fibroblasts showed
that nicotine dose dependently increased cell proliferation (Fig. 6A); miR-24 inhibition also enhanced the proliferation of
human lung fibroblasts (Fig. 6B). Notably, FGF is a predicted
miR-24 target that is also regulated by nicotine (Fig. 12). Basic FGF is essentially involved in the stimulation of fibroblasts
and maintenance of their growth (Makino et al., 2010; Xiao
et al., 2012). Overproliferation of fibroblasts is believed to
contribute to abnormal deposition of an extracellular matrix
in the lungs (Kendall and Feghali-Bostwick, 2014).

Nicotine Increased Soluble Collagen Release by Lung Fibroblasts. Measurement of collagen in TGFβ1-treated lung
fibroblasts showed that cotreatment with nicotine significantly
increased the amount of soluble collagen being released into the
conditioned media (Fig. 7). However, selective miR-24 inhibi-
tion did not reproduce this effect. Several studies have reported
that nicotine increases TGFβ1 expression and accelerates
collagen accumulation in various cell types and organ
systems (Sekhon et al., 2002; Goette et al., 2007; Rehan et al.,
2007; Shan et al., 2009; Takeuchi et al., 2010; Soeda et al.,
2012; Vicary et al., 2017). In addition, analysis of hits from our
TaqMan OpenArray Human Inflammation Panel (Life Tech-
nologies) indicates that nicotine treatment of human lung
fibroblasts modulated the expression of several genes, includ-
ing those related to innate immunity (e.g., NfκB, MEFV, and
toll-like receptors), ligand-gated ion channels (e.g., ryanodine
receptor 1 and purinergic receptor 7), oxidative stress (e.g.,
NADPH oxidase 4), and extracellular matrix turnover (e.g.,
bone morphogenetic protein 6) (Supplemental Fig. 3).

Nicotine Enhances the Release of Growth Factors from Lung Cells. ELISA-based measurement of growth factors (PDGF, FGF, and VEGF) in lung endothelial cells,
a cell type known to be a major source of growth factors in
physiologic and pathologic conditions (Bauters et al., 1999),
showed enhanced secretion of these growth factors into
conditioned media following nicotine stimulation (Fig. 8).
Several studies in different cell types have reported the
angiogenic property of nicotine, including excessive stimu-
lation of growth factors (Cucina et al., 2000; Heeschen et al.,
2001; Conklin et al., 2002; Grozio et al., 2007; Jensen et al.,
2012). Similarly, inhibition of miR-24 with an antagon-
imicked the effect of nicotine, resulting in increased levels
of all three growth factors (Fig. 9). Overstimulation of the
mitogenic growth factors PDGF, FGF, and VEGF is implicated
in the pathogenesis of lung fibrosis, and modulation of how
these growth factors interact with their tyrosine kinase recep-
tors is the basis for the pharmacological action of nintedanib;
one of only two Food and Drug Administration–approved drugs
for the treatment of IPF (Richeldi et al., 2014).

Prolonged Nicotine Exposure Upregulates the Expression of Myofibroblast Markers. Our immunofluores-
cence data demonstrate that prolonged exposure of lung
fibroblasts to clinically relevant concentrations of nicotine
increases the expression of the myofibroblast markers
α-SMA and type I collagen (Fig. 10), suggesting that
nicotine directly contributes to the expansion of collagen-
producing cells that form the basis of fibrotic lesions and
matrix stiffness.

The Expression of Growth Factors Is Increased in
IPF. Lung epithelial single cell RNA sequencing analysis from
the lung gene expression analysis web portal (Du et al.,
2015, 2017) comparing single cells isolated from IPF patients and control lungs validated that expression of the three growth factors (PDGF, FGF, and VEGF) is increased in IPF compared with controls (Fig. 11).

**Discussion**

Several studies have demonstrated the expression of functional nAChRs in lung cells (Kummer et al., 2008; Maouche et al., 2009; Kummer and Krasteva-Christ, 2014). For example, Maouche et al. (2013) reported that α7 nAChR plays a major role in nicotine-mediated airway epithelium dysfunction. Additional studies (Sekhon et al., 1999, 2001; Wongtrakool et al., 2007; Maouche et al., 2009) have reported that the α7 nAChR controls lung development and morphogenesis, including airway epithelial cell proliferation and differentiation, suggesting a key role of this nAChR subunit in airway remodeling and plasticity (Fig. 1).

Given the significance of the nAChRs in lung pathobiology, and the difficulty of characterizing all of the 5000 components of cigarette smoke, our current study was focused on the mechanisms by which a chief ingredient of tobacco smoke (i.e., nicotine) is associated with proinflammatory and profibrotic phenotypes in lung cells. Our preclinical study in an animal model of bleomycin-induced lung fibrosis revealed that miR-24, a microRNA recently reported to be significantly dysregulated in a major tobacco smoke–related vascular disease (Maegdefessel et al., 2014), was significantly downregulated upon lung injury (Fig. 2). This in vivo inhibition of miR-24 was reproduced in vitro upon treatment of lung epithelial cells with clinically relevant concentrations of nicotine (Fig. 3). In addition, our findings demonstrate that clinically relevant doses of nicotine upregulate proinflammatory, profibrotic, and proangiogenic molecules (Figs. 5–8 and 10). The inflammatory molecules that we found to be upregulated by nicotine include TNFα, IL1β, and NFκB. The induced expression of these inflammatory molecules by nicotine was also mirrored by genetic ablation of miR-24 (Fig. 4), suggesting that nicotine controls these molecules at least in part through the inhibition

---

**Fig. 6.** The proliferation of lung fibroblasts is increased upon treatment with: (A) nicotine (1–100 nM) or (B) miR-24 inhibitor (3–100 nM). Synchronized primary human lung fibroblasts (seeding density = 3 × 10^4) were treated with nicotine, miR-24 inhibitor, or control for 24 hours and allowed to proliferate in the presence of BrdU for an additional 22 hours. Cell proliferation was assessed using BrdU assay. Data are mean ± S.E.M. from duplicate experiments (n = 3) and are expressed as the percentage of proliferation in the control groups. *P < 0.05 vs. control; miR-24 Inh denotes miR-24 inhibitor.

**Fig. 7.** Nicotine enhances soluble collagen release by lung fibroblasts. Primary human lung fibroblasts were seeded at 6 × 10^4 cells/well in six-well plates. Synchronized cells were treated with recombinant human TGFβ1 (10 ng/ml) in the presence of nicotine (100 nM), miR-24 inhibitor (30 nM), or vehicle for 24 hours. Acid-soluble collagen content in each well was determined in the conditioned media using Sircol collagen assay. The amount of collagen in each well was estimated from a standard curve and the collagen content in each sample was normalized to total cellular protein. Data are mean ± S.E.M. from duplicate experiments (n = 3). *P < 0.05 compared with no TGFβ control.

**Fig. 8.** Nicotine increases the expression of growth factors PDGF, FGF, and VEGF in lung endothelial cells. Primary human lung endothelial cells were seeded on 75 cm^2 flasks until 80% confluency, and then treated with nicotine (1–100 nM) or control (PBS) for 24 hours. The concentration of the growth factors in the conditioned media was measured by ELISA (optical density: 450 nm readout) and calculated from the standard curve. Data were normalized to total cellular protein and are expressed as mean ± S.E.M. from duplicate experiments (n = 3). *P < 0.05 vs. control.
endothelial cells were seeded on 75 cm² flasks until 80% confluency, and then treated with miR-24 inhibitor (100 nM) or control miR for 24 hours. The intracellular growth factor concentration was measured by ELISA (optical density: 450 nm readout) and calculated from the standard curve. Data were normalized to total cellular protein and are expressed as mean ± S.E.M. from duplicate experiments (n = 3). *P < 0.05 vs. control.

of miR-24. In addition to the proinflammatory role, we found that nicotine was able to increase the amount of collagen secreted by lung fibroblasts in a miR-24-independent manner (Fig. 7), suggesting that nicotine does not directly depend on this miR to enhance collagen release. Our data also show that nicotine directly increased the proliferation of human lung fibroblasts (Fig. 6A) and their transition into myofibroblast-like cells (Fig. 10), suggesting the expansion of collagen-producing cells upon prolonged exposure to nicotine. This accelerated proliferation of lung fibroblasts by nicotine needs to be evaluated in other lung cell types, such as epithelial and endothelial cells, since a change in their proliferation kinetics may influence the course of inflammation and fibrosis in IPF (Willis et al., 2005; Selman and Pardo, 2006; Akram et al., 2014; Piera-Velazquez et al., 2016). Finally, the proangiogenic molecules PDGF, FGF, and VEGF were significantly induced by exposure of lung endothelial cells to nicotine (Fig. 8) or upon inhibition of miR-24 by an antagonim; albeit to a lesser extent (Fig. 9). These findings suggest that nicotine is partially dependent on miR-24 to regulate levels of these growth factors in lung endothelial cells. The inhibition of growth factors by nicotine is consistent with the mitogenic property of nicotine reported in the literature (Cucina et al., 2000; Heeschen et al., 2001; Conklin et al., 2002; Grozio et al., 2007; Jensen et al., 2012). Similarly, our analysis of the lung gene expression analysis web portal confirmed that the expression of PDGF, FGF, and VEGF is upregulated in lung epithelial cells derived from IPF patients compared with controls (Fig. 11). In general, the induction of these growth factors is believed to be positively associated with the disease process in IPF (Antoniades et al., 1990; MacKenzie et al., 2015; Atamas, 2017). For example, PDGF is known to act as a chemo-attractant for lung fibroblasts and stimulate the accumulation of abnormal levels of collagen (Antoniades et al., 1990). Nintedanib, a drug that works by inhibiting the receptors for PDGF, FGF, and VEGF, has been shown to slow the rate of decline in lung function in patients with IPF (Richeldi et al., 2014).

Overall, our study provides some important insights into the mechanism(s) by which nicotine contributes to the development and/or progression of lung fibrosis. Our data suggest that nicotine may accelerate the disease process in IPF through excessive stimulation of growth factors and down-regulation of anti-inflammatory miRs. The existing literature indicates that nicotine, through its receptors, is able to stimulate growth factors (Ng et al., 2007), induce oxidative stress (Barr et al., 2007), and promote inflammation (Hosseinizadeh et al., 2016). The stimulated proinflammatory molecules (Bringardner et al., 2008), mitogenic growth factors (Allen and Spiteri, 2002), and pro-oxidants (Cheresh et al., 2013) are known to promote lung inflammation and fibrogenesis (Fig. 12). Added to the existing literature is our study linking the effect of nicotine on anti-inflammatory microRNA. To date, the role of only a handful of microRNAs has been demonstrated in the IPF disease process. However, the effect of tobacco smoke or nicotine on lung miRs has not been fully explored. This differential effect of nicotine on growth factors and miRs has important implications in a number of respiratory diseases that extend beyond IPF. In the context of IPF, our study sheds some light on possible links between tobacco use, increased risk of lung disease, and subsequent

Fig. 9. Inhibition of miR-24 increases the expression of growth factors PDGF, FGF, and VEGF in lung endothelial cells. Primary human lung endothelial cells were seeded on 75 cm² flasks until 80% confluency, and then treated with miR-24 inhibitor (100 nM) or control miR for 24 hours. The intracellular growth factor concentration was measured by ELISA (optical density: 450 nm readout) and calculated from the standard curve. Data were normalized to total cellular protein and are expressed as mean ± S.E.M. from duplicate experiments (n = 3). *P < 0.05 vs. control.

Nicotine Enhances Inflammatory and Fibrotic Processes

Fig. 10. Immunofluorescence stain showing increased expression of the myofibroblast markers α-SMA and collagen I upon chronic exposure of lung fibroblasts to nicotine. Primary human lung fibroblasts were seeded in six-well plates and treated with nicotine (100 nM) daily for 5 days. The cells were fixed, permeabilized, and stained for the myofibroblast markers: α-SMA (1:400; Abcam), and collagen I (1:500; Abcam) (n = 3). Goat anti-rabbit (1:500; ThermoFisher) Alexa Fluor 594 secondary antibodies were used and are shown as red stain. The nuclei were stained with 4’,6-diamidino-2-phenylindole and are shown as blue stain. Objective original magnification, 40×; Scale bar, 50 μm (applies to all the images in this figure).
accelerated loss of lung function (Oh et al., 2012). The conflicting data on the effect of tobacco smoke (e.g., the “healthy smoker effect”) on the incidence and severity of some chronic lung diseases and overall survival of patients (Valeyre et al., 1988; Peros-Golubicic and Ljubić, 1995; Vassallo and Ryu, 2012; Margaritopoulos et al., 2015) may be reconciled by understanding the differential contribution of major tobacco smoke components on the pathophysiology of lung cells, including cell survival and function.

In conclusion, we have linked the simultaneous effect of nicotine on growth factors and microRNA in lung cells. Further mechanistic understanding of the pathologic effect of nicotine in cigarette smoke is likely to unlock additional research opportunities to study possible adverse effects of the nicotine present in e-cigarettes, chewing tobacco, and nicotine replacement therapy (a current interventional strategy developed for the cessation of mainstream tobacco smoke).

Fig. 11. The gene expression of VEGF (isoforms A and C), PDGF (isoforms A, B, and C), and FGF-2 is increased in lung epithelial cells isolated from IPF patients compared with controls. Data are curated from RNA sequencing analysis from the lung gene expression analysis web portal comparing single cells isolated from IPF patients and control lungs.

In Fig. 12, we schematically show the potential mechanism of accelerated lung inflammation and fibrosis by nicotine. As shown, nicotine internalizes through the endogenous nAChRs to promote growth factors (VEGF, FGF, and PDGF) and induce oxidative stress, which in turn stimulates profibrotic molecules (TGFβ, collagen, fibronectin, and metalloproteinases). In addition, we propose that nicotine suppresses anti-inflammatory microRNA such as miR-24 to derepress the expression of inflammatory cytokines including TNFα, NFκB, and interleukins, which are known to interact with mitogenic growth factors and profibrotic molecules to promote aberrant lung remodeling.


Authorship Contributions
Participated in research design: Ebrahimpour, Shrestha, Ghebre.
Conducted experiments: Ebrahimpour, Shrestha, Ghebre.
Contributed new reagents or analytic tools: Ebrahimpour, Ghebre.
Performed data analysis: Ebrahimpour, Ghebre.
Wrote or contributed to the writing of the manuscript: Bonnin, Eissa, Raghu, Ghebre.

References


Belaye PS and Koll M (2015) Why do patients get idiopathic pulmonary fibro-


Address correspondence to: Dr. Yohannes Ghebre, Department of Radiation Oncology, Baylor College of Medicine, One Baylor Plaza, Neurosensory Building NB335, Houston, TX 77030. E-mail: yohannes.ghebre@bcm.edu